How does fluid overload with vascular congestion and cardiorenal syndrome cause acute kidney injury, and will removal of excess fluid improve the response to increased torsemide (loop diuretic)?

Fluid Overload and Cardiorenal Syndrome in AKI: Decongestion Strategy

Yes, aggressive fluid removal will likely improve torsemide response and kidney function in cardiorenal syndrome with vascular congestion—venous congestion is a direct, reversible cause of AKI that impairs diuretic efficacy, and successful decongestion can restore both renal function and diuretic responsiveness.

Pathophysiology: How Congestion Causes AKI

Fluid overload with vascular congestion causes AKI through renal venous hypertension, not just arterial underfilling 1, 2. When central venous pressure rises above 6-8 mmHg, it directly transmits backward pressure to the renal veins 3. This creates a cascade:

• Increased renal interstitial hydrostatic pressure within the non-distensible renal capsule compresses tubules and peritubular capillaries 4, 5
• Reduced net ultrafiltration pressure at the glomerulus decreases GFR even when arterial pressure is normal 5
• Tubular compression and hypoxia from interstitial edema causes direct tubular injury 4, 5
• Impaired lymphatic drainage fails under sustained congestion 5

The cardiorenal syndrome perpetuates itself: renal dysfunction → sodium retention → worsening volume overload → peripheral vasoconstriction and hypoxia → further deterioration of renal blood flow 1.

Why Congestion Impairs Diuretic Response

Higher venous congestion grades directly reduce loop diuretic efficiency 6. In a 2025 study, patients with VExUS grade 2-3 had significantly lower urine output per 40mg furosemide compared to grade 0-1 (270-333 mL vs 507 mL, p<0.02) 6. This relationship was independent of baseline creatinine or prior diuretic use.

The mechanisms include:

• Reduced tubular delivery: Elevated renal venous pressure decreases the drug reaching its luminal site of action 1, 7
• Decreased nephron number: Progressive congestion reduces functional nephron mass 8
• Neurohormonal activation: Loop diuretics paradoxically activate RAAS, creating a vicious cycle requiring dose escalation 9
• Gut wall edema: Reduces oral bioavailability of diuretics in fluid-overloaded states 8

Evidence That Decongestion Improves Renal Function

In patients with severe volume overload, diuresis can actually improve renal function 1, 10. This occurs through a "left shift from the extreme right of the Starling curve," allowing stroke volume to increase 1. The 2019 ACC pathway explicitly states that serum creatinine commonly rises slightly during effective decongestion but generally returns to baseline early after discharge and is not associated with worse outcomes when accompanied by adequate decongestion 10.

The 2020 ESC position statement confirms: successful decongestion was associated with better outcomes (hospitalization, survival) than partial decongestion, even when creatinine transiently increased 11. Improvement in VExUS grade at 72 hours correlated with significant renal function improvement (84.6% vs 47.1%, p=0.03) 6.

Practical Management Strategy

Step 1: Assess Congestion Status

• Clinical: JVP elevation, peripheral edema, ascites, pulmonary rales
• Hemodynamic: CVP >6-8 mmHg indicates renal risk 3
• Ultrasound: VExUS grading with renal venous stasis index (RVSI) best predicts diuretic efficiency (AUROC 0.76) 6
• Biomarkers: Spot urine sodium <50-70 mEq/L at 2 hours indicates poor diuretic response 11

Step 2: Optimize Diuretic Strategy for Congestion

For torsemide specifically 7:

• Oral bioavailability ~80% with minimal first-pass metabolism
• Longer duration of action (12-16 hours) vs furosemide (6-8 hours) 8
• In hepatic cirrhosis (common in cardiorenal syndrome), volume of distribution doubles but total clearance unchanged 7
• Switch from oral to IV dosing at 1-2.5× home dose if gut edema suspected 10

Combination diuretic therapy 1, 10, 12:

• Add acetazolamide 500mg bolus + 500mg/day infusion to loop diuretics for superior decongestion 12
• Alternative: thiazide-type diuretic (metolazone 2.5-5mg) to block distal sodium reabsorption 1, 10
• Continuous infusion superior to bolus dosing for sustained effect 1

Step 3: Monitor Response and Adjust

Target metrics 11:

• Urine output >100-150 mL/hour in first 6 hours
• Spot urine sodium >50-70 mEq/L at 2 hours post-diuretic
• Daily weight loss 1-2 kg
• Improvement in VExUS grade by 72 hours

If inadequate response despite high-dose diuretics 1, 10, 13:

• Consider ultrafiltration or hemodialysis for refractory congestion
• Protocolized fluid removal by diuretics reduces RRT risk (RR 0.72,95% CI 0.55-0.96) 13
• Ultrafiltration reserved for diuretic-resistant cases—no mortality benefit but effective fluid removal 10, 13

Critical Pitfalls to Avoid

1. Don't confuse "pseudo-WRF" with true AKI: Creatinine rise during effective decongestion with good urine output is not harmful and often reverses 10, 11. The key is achieving decongestion.

2. Don't stop diuretics for rising creatinine if still congested: Persistent congestion is more harmful than transient creatinine elevation 11. Only reduce diuretics if signs of hypovolemia (hypotension, low urine sodium despite diuretics).

3. Monitor electrolytes daily: Hypokalemia, hypomagnesemia reduce diuretic efficacy 1. Correct before escalating doses.

4. Avoid excessive vasodilation: In cardiorenal syndrome, maintain adequate mean arterial pressure for renal perfusion while relieving venous congestion 1, 5.

5. Recognize diuretic resistance early: If urine sodium <50 mEq/L at 2 hours, escalate immediately rather than waiting days 11.

Special Considerations for Torsemide

Torsemide has advantages in cardiorenal syndrome 7:

• More predictable absorption than furosemide
• Longer half-life allows once-daily dosing
• In heart failure, hepatic and renal clearance both reduced, but smaller fraction delivered intraluminally means higher doses needed (up to 200mg daily studied) 7
• Renal clearance markedly decreased in renal failure, but total plasma clearance unchanged 7

The 2023 Canadian guidelines recommend early SGLT2 inhibitor initiation alongside diuretics for additional decongestion and renal protection 12, though this addresses chronic management rather than acute response.

Bottom line: Venous congestion directly impairs both kidney function and diuretic response through elevated renal venous pressure. Aggressive, monitored decongestion will improve torsemide efficacy and can restore renal function, even if creatinine transiently rises during the process. Use combination diuretics, monitor urine sodium response, and target complete decongestion rather than arbitrary creatinine thresholds.